Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
Executive Summary
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.